- Policy
- Finalized gradual drug pricing in effect from July
- by Kim, Jung-Ju Mar 4, 2020 06:27am
- The government finalized the so-called ‘gradual drug pricing system revision’ that differentiates reimbursed generic pricing based on individual bioequivalence test. The approval qualification and pricing linkage, such as conducting individual bioequivalence test and using registered substance with DMF, would come in effect from July 1. Wh
- Company
- Eisai’s low-dose Pariet passed by general hospital DCs
- by Eo, Yun-Ho Mar 3, 2020 06:10am
- Low-dose Pariet is landing on general hospital prescription code. Pharmaceutical industry source reported Drug Committees in Severance Hospital, Samsung Medical Center, and Korea University Guro Hospital cleared proton pump inhibitor (PPI) Pariet 5 mg tablet (rabeprazole sodium), which received National Health Insurance reimbursement in
- Opinion
- [Reporter’s View] Irony in group-listing competing drugs
- by Eo, Yun-Ho Mar 3, 2020 06:10am
- Inducing competition between pharmaceutical companies could lessen the financial exhaustion, but National Health Insurance (NHI) reimbursement listing procedure would get delayed. Such is an irony we witness during high-cost new drug listing or reimbursement expansion procedures in Korea. The government could take an advantage of price co
- Policy
- The supply cost of NIP quadrivalent flu vaccine is absurd
- by Lee, Tak-Sun Mar 3, 2020 06:09am
- Manufacturers are opposing the government's pricing policy ahead of the Quadrivalent flu Vaccine (NIP) program. Damages will be inevitable by setting a budget without considering production costs more expensive than trivalent vaccines. In particular, pharmaceutical companies are complaining that they have to take losses because medical
- Policy
- MOHW to speed up anticancer therapy reimbursement review
- by Lee, Jeong-Hwan Mar 3, 2020 06:09am
- The Korean health authority is to expedite the reimbursement review procedure for the latest anticancer therapies including Imfinzi, Bavencio, and Tecentriq. The authority is also reviewing data submitted by Opdivo and Keytruda for their additional indications. On Feb. 28, Ministry of Health and Welfare (MOHW) Pharmaceutical Benefits
- Policy
- The government invests ₩16 trillion for COVID-19
- by Lee, Jeong-Hwan Mar 3, 2020 06:09am
- The government announced on the 28th that it would invest about &8361;16 trillion to finance, tax and banking to solve the problems caused by the spread of COVID-19. From March to June, the check and credit card income deduction rate will be doubled to the previous level, and individual consumption tax will be cut by 70%. VAT payments
- Antidiabetic prescription trend shifts along CVD-HF option
- by Won, Jong-Hyeok Mar 2, 2020 06:23am
- An analysis research on last five years found oral SGLT2 inhibitor medications and GLP-1 receptor agonist injections have been highly preferred for type 2 diabetes prescription. By expanding an indication to benefit cardiovascular system, these medications have been highly favored by prescribers to treat diabetic patients who experienced myo
- Company
- GSK speeds up development of COVID-19 vaccine
- by Eo, Yun-Ho Mar 2, 2020 06:22am
- GSK is focusing its capabilities on developing the COVID-19 vaccine GSK recently announced cooperation with China's biotech company Clover, following the Coalition for Epidemic Preparedness Innovations (CEPI). Together, Clover and GSK will jointly develop a protein-based COVID-19 vaccine candidate (COVID-19 S-Trimer). GSK will provid
- Policy
- Remdesivir, Phase III clinical trials are imminent in Korea
- by Lee, Tak-Sun Mar 2, 2020 06:22am
- Gilead has applied for Remdesivir’s IND for COVID-19 patients at the MFDS. In Asian countries, including Korea (excluding China), the study targets 1000 patients. There is no country-specific number of subjects, but it is known to be recruited on a first come, first served basis. The MFDS announced that Gilead submitted a Phase III cli
- Policy
- Single Hib vaccine Vaxem Hib exits Korean market
- by Lee, Tak-Sun Mar 2, 2020 06:21am
- Apparently, there are now only two single Haemophilus influenzae type b (Hib) vaccines left in the market that prevents cerebromeningitis in children by blocking Hib bacteria. Experts analyze, although a part of National Immunization Program, single Hib vaccine has lost its competitiveness in Korean market against other combination vac
